Abstract 1095: In silico mapping of oncogene networks implicate the WNT pathway in the glioblastoma MES subtype

Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA It is clear that glioblastoma (GBM) is a collection of molecular subtypes, however little is known of their oncogene signaling. To address this we are currently developing a new method to map PI3K/AKT/mTOR network activity. It uses TCGA reverse-phase protein array data and is based on correlations between active pathway members. This approach provides evidence the WNT pathway is active in the Mesenchymal subgroup and we are currently validating these results. Based on this data we hypothesize Mesenchymal patients will respond to WNT inhibitors. Citation Format: Anna M. Joy, Ivan Smirnov, Mark Reiser, Seungchan Kim, Burt Feuerstein. In silico mapping of oncogene networks implicate the WNT pathway in the glioblastoma MES subtype. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1095. doi:10.1158/1538-7445.AM2015-1095